| Expression pattern: |
DN |
| Associated gene: |
HIF-1alpha, Ago2, caspase 3, BCL-2, BAX, cleaved-caspase 3, pro-caspase 3 |
| Associated microRNA: |
miR-29a-3p |
| Biological function: |
circLRP6 inhibits AAA development and progression; circLRP6 overexpression inhibits Ang II-induced hAoSMC cell viability and proliferation, regulates cell cycle, and induces apoptosis. |
| Molecular mechanism: |
circLRP6 acts through the miR-29a-3p/HIF-1alpha axis, negatively regulates miR-29a-3p, interacts with HIF-1alpha, inhibits HIF-1alpha expression, and modulates apoptosis-related proteins. |
| Biological pathway or process: |
HIF-1 signaling (inhibits); apoptosis (promotes); proliferation (inhibits); cell cycle (other); ceRNA regulation (other) |
| Detected method: |
Q
H
M
|
| Validation methods: |
RNase R Treatment; RT-qPCR; FISH / smFISH; Clinical Sample Validation; Bioinformatics Analysis; Transfection; CCK8; BrdU; Cell Cycle Assay; Annexin V/PI Flow Cytometry; Western Blot; Luciferase Reporter Assay; RIP (RNA Immunoprecipitation); IF (Immunofluorescence); In Vivo Animal Model |
| Clinical significance: |
circLRP6 is proposed as a potential therapeutic target and theoretical basis for clinical optimization of AAA treatment. |
| Description: |
circLRP6 is down-regulated in AAA tissues, Ang II-induced hAoSMCs, and mouse AAA aorta samples. Its overexpression suppresses Ang II-induced hAoSMC viability and proliferation, modulates cell cycle changes, and promotes apoptosis. Mechanistically, circLRP6 functions through a miR-29a-3p/HIF-1alpha-related axis and may serve as a potential therapeutic target for AAA. |
| Confidence score: |
0.78 |